We can't find the internet
Attempting to reconnect
16771.3 PFLS-LS
Determining Patient Risk by Differentiating Aggressive from Nonaggressive Prostate Cancer Using a Serum Protein Risk Stratification Test
Résumé
Determining Patient Risk by Differentiating Aggressive from Nonaggressive Prostate Cancer Using a Serum Protein Risk Stratification Test
Textes supplémentaires
Abstract
The goal of the interdisciplinary ProteoMediX/ETHZ/USZ/FHNW project is to develop an immunoassay-based risk stratification test (PMX-Px) for the prognosis of patients diagnosed|with localized prostate cancer (PCa) by using Mass Spectrometry-GUided Immunoassay DEvelopment (MS-GUIDE). A commercially available kit in the context of personalized|medicine will provide doctors and patients with a tool supporting them in their decision making in between prostatectomy or active surveillance for patients with localized|PCa.
Participants
Bernd Wollscheid
Kontaktperson
wbernd@ethz.ch
ETH Zürich Bernd Wollscheid Auguste-Piccard-Hof 1 8093 Zürich ZH CH
Ralph Schiess
Wirtschaftspartner
schiess@proteomedix.com
ProteoMediX AG Ralph Schiess Wagistrasse 23 8952 Schlieren ZH CH
Détails du projet
- Office de recherche
- INNOSUISSE
- Statut du projet
- Abgeschlossen
- Type de projet
- Forschungsprojekt
- Date de début
- 2015-03-31
- Date de fin
- 2017-12-31
- Coûts totaux approuvés
- CHF 738810.00
- Section
- 20 Förderbereich Life Sciences
- Domaine politique NABS
- Industrielle Produktivität und Technologie
Disciplines de recherche
- T490 Biotechnology 100.0%